The significance of partial volume effect on the estimation of hypoxic tumour volume with [18F]FMISO PET/CT.

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Kafkaletos, Athanasios
  • Mix, Michael
  • Sachpazidis, Ilias
  • Ruhle, Alexander
  • Ruf, Juri
  • Grosu, Anca L
  • Nicolay, Nils H
  • Baltas, Dimos

Grups d'Investigació

Abstract

BACKGROUND: The purpose of this study was to evaluate how a retrospective correction of the partial volume effect (PVE) in [18F]fluoromisonidazole (FMISO) PET imaging, affects the hypoxia discoverability within a gross tumour volume (GTV). This method is based on recovery coefficients (RC) and is tailored for low-contrast tracers such as FMISO. The first stage was the generation of the scanner's RC curves, using spheres with diameters from 10 to 37mm, and the same homogeneous activity concentration, positioned in lower activity concentration background. Six sphere-to-background contrast ratios were used, from 10.0:1, down to 2.0:1, in order to investigate the dependence of RC on both the volume and the contrast ratio. The second stage was to validate the recovery-coefficient correction method in a more complex environment of non-spherical lesions of different volumes and inhomogeneous activity concentration. Finally, we applied the correction method to a clinical dataset derived from a prospective imaging trial (DRKS00003830): forty nine head and neck squamous cell carcinoma (HNSCC) cases who had undergone FMISO PET/CT scanning for the quantification of tumour hypoxia before (W0), 2weeks (W2) and 5weeks (W5) after the beginning of radiotherapy. Here, PVE was found to cause an underestimation of the activity in small volumes with high FMISO signal.; RESULTS: The application of the proposed correction method resulted in a statistically significant increase of both the hypoxic subvolume (171% at W0, 691% at W2 and 4.60*103% at W5 with p<0.001) and the FMISO standardised uptake value (SUV) (27% at W0, 21% at W2 and by 25% at W5 with p<0.001) within the primary GTV.; CONCLUSIONS: The proposed PVE-correction method resulted in a statistically significant increase of the hypoxic fraction (HF) with p<0.001 and demonstrated results in better agreement with published HF data for HNSCC. To summarise, the proposed RC-based correction method can be a useful tool for a retrospective compensation against PVE. © 2024. The Author(s).

Dades de la publicació

ISSN/ISSNe:
2197-7364, 2197-7364

EJNMMI Physics  Springer International Publishing AG

Tipus:
Article
Pàgines:
-
PubMed:
38722446
Factor d'Impacte:
1,031 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 1

Documents

  • No hi ha documents

Mètriques

Filiacions

Filiacions no disponibles

Keywords

  • Hypoxia; Partial volume effects; PET; FMISO; HNSCC

Projectes associats

OPTIMIZACION DE LA QUANTIFICACION EN IMAGEN POR TOMOGRAFIA POR EMISION DE POSITRONES (PET) PARA SU USO EN RADIOTERÀTIA

Investigador Principal: LUIS MARTÍ BONMATÍ

APOSTD2015/017 . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA; CONSELLERIA DE EDUCACION . 2015

3D-Printing phantoms for quality assurance in multimodality imaging.

Investigador Principal: MONTSERRAT CARLES FARIÑA

2022-155-1_CRC_AECC_CARLES . FUNDACIÓN CIENTÍFICA AECC . 2022

Implementación de la compensación del movimiento respiratorio en el diagnóstico y tratamiento radioterápico de pacientes con cáncer de pulmón: protocolos de imagen, segmentación del tumor y garantía de calidad del tratamiento.

Investigador Principal: MONTSERRAT CARLES FARIÑA

PI22/01604 . INSTITUTO DE SALUD CARLOS III . 2023

MATTO-GBM FCAECC-Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma.

Investigador Principal: LUIS MARTÍ BONMATÍ

TRANSCAN-3 JTC2022 . COMISION EUROPEA . 2023

QA-THOMASA - UCIE 22-24

Investigador Principal: MONTSERRAT CARLES FARIÑA

INNVA2/2022/1_THOMASA . 2022

Contrato PFIS 2023. CARMEN SALVADOR RIBES

Investigador Principal: MONTSERRAT CARLES FARIÑA

FI23/00097 . INSTITUTO DE SALUD CARLOS III . 2024

Contrato Miguel Servet 2023. MONTSERRAT CARLES FARIÑA

Investigador Principal: MONTSERRAT CARLES FARIÑA

CP23/00106 . INSTITUTO DE SALUD CARLOS III . 2024

MATTO-GBM ISCIII-Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma.

Investigador Principal: LUIS MARTÍ BONMATÍ

AC23_1/00012 . COMISION EUROPEA . 2024

Acción de fortalecimiento institucional transversal para una medicina 5P (AFIT-5P)

Investigador Principal: JAVIER DE LA RUBIA COMOS

FORT23/00021 . INSTITUTO DE SALUD CARLOS III . 2024

BIOBANCO DEL HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE (BIOBANCO LA FE). PLATAFORMA DE BIOBANCOS Y BIOMODELOS

Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA

PT23/00166 . INSTITUTO DE SALUD CARLOS III . 2024

Compartir la publicació